🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Düsseldorf
Clinical trial register · Germany

Clinical Trials in Düsseldorf, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 1584 Hamburg 889 Essen 760 Dresden 707 Heidelberg 627
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Heinrich-Heine University, Duesseldorf43 AstraZeneca20 Merck Sharp & Dohme LLC13 Hoffmann-La Roche13 Janssen Research & Development, LLC8
Site location
Berlin1584 Hamburg889 Essen760 Dresden707 Heidelberg627
All 635 locations
Target enrolment
to

Trials with a site in Düsseldorf

420 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Active, closed
A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
NCT06782373VEXAS, VEXAS Syndrome
DrugPacritinib
Swedish Orphan Biovitrum
Phase 2
156
Tübingen, Munich, Hamburg, Düsseldorf, Dresden, Lübeck
2025-05-28
Recruiting
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
NCT06499285Myelodysplastic Syndromes
DrugElritercept
Takeda
Phase 3
225
Bonn, Düsseldorf, Leipzig, Halle, Magdeburg, Berlin
2025-05-06
Active, closed
FARAPULSE Workflow Assessment Registry
NCT06656884Atrial Fibrillation (AF)
Boston Scientific Corporation
Observational
524
Düsseldorf, Karlsruhe, München
2025-05-06
Recruiting
Effect of Partially Hydrolyzed Formula With Synbiotics on Skin Barrier Function
NCT06943469Atopic Dermatitis (AD)
Société des Produits Nestlé (SPN)
Not applicable
400
Berlin, Düsseldorf, Frankfurt, Spandau, Wesel
2025-04-10
Recruiting
Anti-hypertensive Therapy and Exercise Treatment to Improve Vascular Health in Patients With Hypertension.
NCT06823570Hypertension, Vascular Function, Fitness Testing, Metabolism Changes
Heinrich-Heine University, Duesseldorf
Not applicable
60
Düsseldorf
2025-04-01
Not yet open
Incidence, Characterisation and Outcome-relevance of Perioperative SGLT2 Inhibitor Associated Ketoacidosis
NCT06838507SGLT2 Inhibitor, Ketoacidosis, Eugylcemic
Heinrich-Heine University, Duesseldorf
Observational
2,000
Düsseldorf
2025-04
Recruiting
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
NCT06989112Endometrial Cancer
DrugsTaxotere·Rilvegostomig·Paraplatin·Taxol
AstraZeneca
Phase 3
600
Berlin, Chemnitz, Dessau, Dresden, Düsseldorf, Essen, Hamburg, Kassel
2025-03-27
Active, closed
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
NCT06840392Hidradenitis Suppurativa
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
565
Freiburg im Breisgau, Würzburg, Frankfurt am Main, Düsseldorf, Merzig, Leipzig, Bad Bentheim, Berlin
2025-03-20
Recruiting
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
NCT06841354Triple Negative Breast Neoplasms
DrugsSacituzumab tirumotecan·Nab-paclitaxel·Gemcitabine·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
1,000
Erlangen, Düsseldorf, Essen, Saarbrücken, Leipzig, Berlin
2025-03-16
Recruiting
BEhavioral and Adherence Model for Improving Quality, Health Outcomes and Cost-Effectiveness of healthcaRe
NCT06856902Cardiovascular Diseases, Endocrinology, Inmunology, Neurology
Technical University of Madrid
Not applicable
3,100
Düsseldorf
2025-03-01
Recruiting
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
NCT06764875HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
DrugsRilvegostomig·Trastuzumab deruxtecan·Trastuzumab·Adrucil
AstraZeneca
Phase 3
840
Augsburg, Bad Saarow, Berlin, Braunschweig, Chemnitz, Düsseldorf, Erlangen, Essen
2025-03-01
Active, closed
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
NCT06619236Platinum-resistant Ovarian Cancer
DrugsRina-S·Pegylated liposomal doxorubicin·Topotecan·Gemcitabine
Genmab
Phase 3
530
Berlin, Bonn, Dresden, Düsseldorf, Essen, Frankfurt, Giessen, Hamburg
2025-02-07
Recruiting
A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
NCT06624670Pyoderma Gangrenosum
DrugsSpesolimab·Prednisolone·Prednisone
LEO Pharma
Phase 3
90
Berlin, Düsseldorf, Erlangen, Essen, Freiburg im Breisgau, Hamburg, Tübingen, Würzburg
2025-02-05
Recruiting
Cyclosporine In Takotsubo Syndrome
NCT05946772Takotsubo Cardiomyopathy
DrugCyclosporine A
University Hospital Heidelberg
Phase 2
204
Bad Nauheim, Berlin, Bonn, Cologne, Dresden, Düsseldorf, Essen, Frankfurt
2025-02-01
Recruiting
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
DrugsFicerafusp alfa·Keytruda·Pembrolizumab
Bicara Therapeutics
Phase 2/3
650
Aachen, Berlin, Braunschweig, Chemnitz, Dresden, Düsseldorf, Essen, Göttingen
2025-01-28
Recruiting
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
NCT06585774Chronic Graft-versus-host-disease
DrugAxatilimab
Incyte Corporation
Phase 3
240
Aachen, Berlin, Bonn, Dresden, Düsseldorf, Erlangen, Essen, Halle
2025-01-21
Recruiting
Lumbar Drainage of Intraventricular Hemorrhage
NCT06510842Intraventricular Hemorrhage, Lumbar Drainage, External Ventricular Drainage
University Hospital Heidelberg
Not applicable
354
Heidelberg, München, Augsburg, Berlin, Düsseldorf, Frankfurt, Göttingen, Mainz
2025-01-16
Recruiting
Impact of [18F] PSMA-1007 Imaging for Primary Staging of Prostate Cancer
NCT06820333Prostate Cancer (Adenocarcinoma)
Heinrich-Heine University, Duesseldorf
Observational
200
Düsseldorf
2025-01-10
Recruiting
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
NCT06712316Non-small Cell Lung Cancer
DrugsPumitamig·Pemetrexed·Paclitaxel·Carboplatin
BioNTech SE
Phase 2/3
1,580
Aachen, Berlin, Chemnitz, Düsseldorf, Erlangen, Esslingen am Neckar, Gauting, Gera
2025-01-07
Active, closed
Weight Reduction With the Low-Insulin-Method - Self Monitoring of Breath Acetone
NCT06745362Overweight and Obese Volunteers
West German Center of Diabetes and Health
Not applicable
42
Düsseldorf
2025-01-01
Recruiting
Early Catheter-directed Treatment of High Risk Pulmonary Embolism
NCT06672081Pulmonary Embolism Acute Massive
Leipzig Heart Science gGmbH
Not applicable
210
Bad Krozingen, Bautzen, Bonn, Düsseldorf, Erfurt, Frankfurt am Main, Halle, Hamburg
2024-12-27
Recruiting
Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation
NCT06501625Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
DrugsIvosidenib·Durvalumab·Gemcitabine·Cisplatin
Institut de Recherches Internationales Servier
Phase 1/2
52
Berlin, Düsseldorf, Frankfurt, Hanover, Ulm
2024-12-16
Recruiting
REdo Transcatheter Aortic VALVE Implantation for the Management of Transcatheter Aortic Valve Failure
NCT06557798Aortic Valve Stenosis
The Leeds Teaching Hospitals NHS Trust
Observational
550
Bad Nauheim, Bad Oeynhausen, Berlin, Cologne, Dortmund, Dresden, Düsseldorf, Frankfurt
2024-12-12
Active, closed
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
NCT06691984Metastatic Castration-resistant Prostate Cancer
DrugsXaluritamig·Cabazitaxel·Abiraterone·Enzalutamide
Amgen
Phase 3
707
Berlin, Dresden, Düsseldorf, Essen, Hamburg, Heidelberg, Jena, Lübeck
2024-12-09
Recruiting
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
NCT06382948Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, ESR1 Gene Mutation
DrugsElacestrant·Everolimus
MedSIR
Phase 3
300
Aschaffenburg, Augsburg, Dessau, Düsseldorf, Essen, Georgsmarienhütte, Worms
2024-12-05
Recruiting
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
NCT06465953Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes (MDS)
DrugsIvosidenib·Azacitidine
Institut de Recherches Internationales Servier
Phase 3
48
Dresden, Düsseldorf, Göttingen, Leipzig, Munich
2024-12-03
Active, closed
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
NCT06694805HIV Infections
DrugsRpv La·Cabotegravir·B/F/TAF
ViiV Healthcare
Phase 3
326
Cologne, Berlin, Düsseldorf, Frankfurt
2024-12-02
Recruiting
Diagnostic Performance of [18F]PSMA-1007 in the Context of Biochemical Recurrence of Prostate Cancer
NCT06657131Prostate Cancer After a Radical Treatment, Biochemical Recurrence of Malignant Neoplasm of Prostate, Biochemical Persistence of Prostate Cancer
Heinrich-Heine University, Duesseldorf
Observational
250
Düsseldorf
2024-11-01
Recruiting
Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis
NCT07426991Multiple Sclerosis, Remitting-Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progress Multiple Sclerosis
Heinrich-Heine University, Duesseldorf
Observational
837
Düsseldorf, Mönchengladbach
2024-11-01
Recruiting
EXtensive mulTilayer stEnt treatmeNt in Aortic disSectiOn
NCT06675617Type B Aortic Dissection
Intressa Vascular SA
Not applicable
72
Düsseldorf, Frankfurt, Kiel, Leipzig, München, Münster
2024-10-30
Recruiting
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
NCT06541704Age-related Macular Degeneration (AMD), Geographic Atrophy (GA)
DrugsCemdisiran·Pozelimab
Regeneron Pharmaceuticals
Phase 3
975
Ulm, Berlin, Frankfurt am Main, Marburg, Neubrandenburg, Bonn, Düsseldorf, Münster
2024-10-30
Recruiting
TAVR: The Impact of Prothesis Positioning on Valvular and Coronary Hemodynamics
NCT06896227Transcatheter Aortic Valve Replacement, Transcatheter Aortic Valve Implantation, Commissural Alignment, Commissural Misalignment
Heinrich-Heine University, Duesseldorf
Not applicable
100
Düsseldorf
2024-10-22
Recruiting
Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia
NCT06648889T-ALL
DrugsIsatuximab·Bortezomib
Goethe University
Phase 2
28
Augsburg, Berlin, Bremen, Dresden, Düsseldorf, Erlangen, Frankfurt am Main, Hamburg
2024-10-22
Active, closed
Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia
NCT05888922Androgenetic Alopecia, Female Pattern Baldness
DrugMinoxidil
Industrial Farmacéutica Cantabria, S.A.
Phase 3
520
Bad Bentheim, Berlin, Bochum, Darmstadt, Dresden, Düsseldorf, Frankfurt, Freiburg im Breisgau
2024-10-17
Recruiting
Enhancing Palliative Care in ICU
NCT06605079Palliative Care
Charite University, Berlin, Germany
Not applicable
2,040
Mitte, Wedding, Berlin, Düsseldorf, Halle, Neuss, Wittenberg
2024-10-10
Recruiting
A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy
NCT06568237Multiple System Atrophy
DrugEmrusolmin
Teva Branded Pharmaceutical Products R&D LLC
Phase 2
350
Beelitz, Dresden, Düsseldorf, Kassel, Leipzig, Marburg, München, Münster
2024-10-02
Recruiting
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
NCT06469944Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
DrugsPatritumab deruxtecan·Xeloda·Sacituzumab tirumotecan·Leucovorin
Merck Sharp & Dohme LLC
Phase 1/2
160
Heidelberg, Erdgeschoss, Düsseldorf
2024-09-20
Active, closed
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
NCT06431373Uveitis, Posterior, Uveitis, Intermediate, Uveitis
Priovant Therapeutics, Inc.
Phase 3
371
Mannheim, Bonn, Düsseldorf, Münster, Kiel, Mainz
2024-09-11
By invitation
DESI - Düsseldorfer ESD Study
NCT06993402Oesophageal Tumour, Gastric Tumours, Duodenal Tumours, Colon Tumours
Torsten Beyna
Observational
1,000
Düsseldorf
2024-09-10
Active, closed
Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome
NCT06315751Tourette Syndrome
Noema Pharma AG
Phase 2
164
Düsseldorf, Hanover, Munich
2024-09-10
Active, closed
RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms
NCT06243458Low Risk Myelodysplastic Syndromes
DrugRVU120
GCP-Service International West GmbH
Phase 2
41
Düsseldorf, Leipzig, Münster
2024-09-10
Recruiting
Bilateral Subthalamic Stimulation in PD Patients With Impulse Control Disorders - STIMPulseControl
NCT06498349Parkinson Disease, Impulse Control Disorders
University of Kiel
Not applicable
60
Cologne, Dresden, Düsseldorf, Hamburg, Kiel, Marburg, Mitte, Tübingen
2024-09-05
Recruiting
STIMPulseControl Ancillary Speech Study
NCT06561919Parkinson Disease, Impulse Control Disorder
Steffen Paschen
Not applicable
60
Cologne, Dresden, Düsseldorf, Hamburg, Kiel, Marburg, Mitte, Tübingen
2024-09-05
Recruiting
CRS Questionnaire Validation Project
NCT06970977Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
The European Forum for Research and Education in Allergy and Airway Diseases
Observational
1,000
Düsseldorf, Munich
2024-09-01
Active, closed
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
NCT06486441Endometrial Cancer
DrugsAdriamycin·Taxol·Sacituzumab Govitecan·Doxorubicin
Gilead Sciences
Phase 3
640
Bad Homburg, Düsseldorf, Essen, Hamburg, Hanover, Leipzig, München, Ulm
2024-08-28
Recruiting
A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease
NCT06565195Parkinson's Disease
Prevail Therapeutics
Phase 1
124
Düsseldorf, Münster
2024-08-27
Recruiting
Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma
NCT06440993Extrahepatic Cholangiocarcinoma, Unresectable Perihilar or Ductal CCA
DrugsDurvalumab·Gemcitabine·Cisplatin
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
42
Aachen, Bonn, Cologne, Düsseldorf, Frankfurt, Göttingen, Hanover, Lübeck
2024-08-23
Active, closed
Extra Wide Field of View Lens Study
NCT06483503Colonic Polyp
Pentax Medical
Observational
60
Düsseldorf
2024-08-21
Recruiting
Chronic Outcome Monitoring for DBS in Dystonia
NCT07244549Dystonia
Charite University, Berlin, Germany
Observational
25
Hanover, Düsseldorf, Berlin
2024-08-16
Recruiting
One-Month DAPT in CABG Patients
NCT05997693Chronic Coronary Disease
DrugsTicagrelor·Aspirin
Weill Medical College of Cornell University
Phase 3
700
Düsseldorf, Essen, Freiburg im Breisgau, Giessen, Jena, München, Stuttgart
2024-08-15
Recruiting
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
NCT06549595Untreated Follicular Lymphoma
DrugsSurovatamig·R-Chop
AstraZeneca
Phase 3
1,018
Berlin, Deggendorf, Düsseldorf, Göttingen, Hamburg, Heidelberg, Jena, Karlsruhe
2024-08-07
Recruiting
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
NCT06445972Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
DrugsPatritumab deruxtecan·Ramucirumab·Sacituzumab tirumotecan·Paclitaxel
Merck Sharp & Dohme LLC
Phase 1/2
210
Heidelberg, Erdgeschoss, Düsseldorf
2024-08-07
Recruiting
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
NCT06380751Advanced Breast Cancer
DrugsSaruparib·Camizestrant·Exemestane·Anastrozole
AstraZeneca
Phase 3
788
Aachen, Augsburg, Berlin, Cologne, Dessau, Düsseldorf, Erlangen, Göttingen
2024-08-01
Active, closed
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
NCT06459180Cervical Cancer
DrugsTisotumab Vedotin·Vinorelbine·Topotecan·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 3
686
Heidelberg, Heilbronn, Schwäbisch Hall, Munich, Marburg, Düsseldorf, Essen, Worms
2024-07-24
Active, closed
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)
NCT06355531Progressive Supranuclear Palsy
Ferrer Internacional S.A.
Phase 2
241
Beelitz, Düsseldorf, Leipzig, Munich
2024-07-23
Active, closed
A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy
NCT06384261Leukemia, Myeloid, Acute
DrugsCusatuzumab·Azacitidine·Venetoclax
OncoVerity, Inc.
Phase 2
140
Düsseldorf, Frankfurt, Kiel
2024-07-22
Active, closed
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
NCT06455202Chronic Spontaneous Urticaria
DrugBarzolvolimab
Celldex Therapeutics
Phase 3
976
Aachen, Bad Bentheim, Berlin, Bonn, Dresden, Düsseldorf, Essen, Hamburg
2024-07-19
Recruiting
German-funded Laparoscopic Approach to Cervical Cancer
NCT06489795Cervical Cancer
Hannover Medical School
Not applicable
756
Ludwigsburg, Tübingen, Bad Homburg, Göttingen, Hanover, Lüneburg, Bielefeld, Düsseldorf
2024-07-17
Recruiting
Dapansutrile in Diabetes and Diabetes-Related Complications - Dapan-Dia
NCT06047262Diabetes Mellitus, Type 2
DrugDapansutrile
Marc Donath
Phase 2
300
Düsseldorf
2024-07-09
Not yet open
Perioperative Management & Outcome Following Preoperative Transthoracic Echocardiography in Noncardiac Surgery Patients
NCT06409234Elective Surgical Procedure
European Society of Anaesthesiology
Observational
8,250
Düsseldorf
2024-06-30
Recruiting
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
NCT06463587Generalized Myasthenia Gravis
DrugCladribine
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 3
264
Ulm, Göttingen, Hanover, Bochum, Düsseldorf, Dresden, Leipzig, Lübeck
2024-06-25
Recruiting
Measuring Silent Disease Progression in Multiple Sclerosis With a Multimodal Approach
NCT06501950Multiple Sclerosis
Heinrich-Heine University, Duesseldorf
Observational
77
Düsseldorf
2024-06-20
Recruiting
Strategies for Adaptive Follow-up and Evaluation - Guiding Use of Indicators for De-Escalation in Multiple Sclerosis
NCT06461481Multiple Sclerosis
Heinrich-Heine University, Duesseldorf
Observational
150
Düsseldorf
2024-06-15
Recruiting
Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer
NCT06122584Prostate Cancer
Drug18F-PSMA-1007
ABX advanced biochemical compounds GmbH
Phase 3
380
Dresden, Düsseldorf, Gronau, Hamburg, Leipzig, München, Münster, Rostock
2024-06-13
Active, closed
Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
NCT06284122Follicular Lymphoma
DrugsBendamustin·Vincrystine·Mosunetuzumab·Obinutuzumab
The Lymphoma Academic Research Organisation
Phase 3
790
Amberg, Bamberg, Berlin, Bremen, Chemnitz, Düsseldorf, Frankfurt, Freiburg im Breisgau
2024-06-07
Recruiting
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
NCT06479135Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis
DrugsNavtemadlin·Jakavi·Ruxolitinib
Kartos Therapeutics, Inc.
Phase 3
600
Düsseldorf, Freiburg im Breisgau, Halle, Hamburg, Hanover, Heidelberg, Jena, Kiel
2024-06-03
Recruiting
Determination of Prostate-specific Antigen in Capillary Blood (PSA-Cap)
NCT06626386Prostate Cancer
Heinrich-Heine University, Duesseldorf
Observational
200
Düsseldorf
2024-06-01
Recruiting
Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer
NCT06474806Prostate Cancer
Curasight
Phase 2
168
Chemnitz, Düsseldorf, Hamburg, Munich
2024-06-01
Active, closed
Migraine Research with Smartwatch Application
NCT06862544Migraine
Heinrich-Heine University, Duesseldorf
Observational
55
Düsseldorf
2024-05-17
Active, closed
The OPBC-07/microNAC Study
NCT06529302Breast Cancer
University Hospital, Basel, Switzerland
Observational
2,000
Augsburg, Düsseldorf, Essen, Heidelberg, Lübeck
2024-05-15
Recruiting
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
NCT05980806Myelofibrosis, Moderate Thrombocytopenia, Mild Thrombocytopenia
DrugsMomelotinib·Pacritinib·Selinexor·Ruxolitinib
Karyopharm Therapeutics Inc
Phase 2
58
Düsseldorf, Jena
2024-04-22
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
DrugTeriflunomide
Sanofi
Phase 3
2,500
Bayreuth, Berlin, Bochum, Dresden, Düsseldorf, Essen, Giessen, Hamburg
2024-04-16
Recruiting
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
NCT06312176Breast Neoplasms
DrugsLiposomal doxorubicin·Sacituzumab tirumotecan·Nab-paclitaxel·Capecitabine
Merck Sharp & Dohme LLC
Phase 3
1,200
Erlangen, München, Potsdam, Georgsmarienhütte, Düsseldorf, Essen, Saarbrücken, Gera
2024-04-14
Recruiting
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
NCT06357533Non-Small Cell Lung Cancer
DrugsRilvegostomig·Datopotamab deruxtecan·Keytruda·Pembrolizumab
AstraZeneca
Phase 3
675
Berlin, Bonn, Cologne, Düsseldorf, Essen, Freiburg im Breisgau, Gauting, Georgsmarienhütte
2024-04-11
Active, closed
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
NCT06220201Multiple Sclerosis, Myasthenia Gravis
DrugsZola-cel·Fludarabine·Cyclophosphamide
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
120
Essen, Magdeburg, Düsseldorf, Erlangen, München
2024-03-28
Recruiting
Multicenter, Interdisciplinary National VEXAS Registry With Accompanying Biomaterial Collection
NCT06377462VEXAS Syndrome
Technische Universität Dresden
Observational
500
Aachen, Chemnitz, Dresden, Düsseldorf, Essen, Göttingen, Hamburg, Jena
2024-03-13
Active, closed
A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer
NCT06348199Non-small Cell Lung Cancer Stage IV
DrugsKeytruda·Pembrolizumab
Samsung Bioepis Co., Ltd.
Phase 3
555
Düsseldorf, Halle, Moers, Neuss
2024-03-12
Recruiting
The NEU-STIM Trial
NCT05942924Infant, Premature, Diseases, Birth, Preterm
Leiden University Medical Center
Not applicable
3,280
Dresden, Düsseldorf, Tübingen
2024-03-11
Active, closed
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
NCT06220604Plaque Psoriasis
DrugsIcotrokinra·Deucravacitinib
Janssen Research & Development, LLC
Phase 3
731
Augsburg, Bad Bentheim, Berlin, Bochum, Darmstadt, Dresden, Dülmen, Düsseldorf
2024-03-09
Recruiting
Mentalization-based Treatment Versus Bona-fide Treatment for Patients With Borderline Personality Disorder in Germany
NCT06018272Borderline Personality Disorder
Heidelberg University
Not applicable
304
Berlin, Düsseldorf, Heidelberg, Jena, Ulm
2024-02-28
Recruiting
NeoRad Breast Cancer Study
NCT04261244Breast Cancer
Bielefeld University
Phase 3
1,826
Ahaus, Bad Homburg, Berlin, Bocholt, Dessau, Detmold, Düsseldorf, Georgsmarienhütte
2024-02-01
Recruiting
Early Percutaneous Transluminal Angioplasty in Diabetic Foot Syndrome (PTA-DFS)
NCT06124586Diabetic Foot, Diabetes Mellitus, Peripheral Arterial Disease, Diabetic Neuropathies
Heinrich-Heine University, Duesseldorf
Not applicable
200
Düsseldorf
2024-02-01
Recruiting
Overfeeding Induced Fat-tissue Stimulation
NCT06193668Lipid-induced Insulin Resistance
German Diabetes Center
Not applicable
32
Düsseldorf
2024-01-31
Active, closed
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06212999Hidradenitis Suppurativa (HS)
DrugPovorcitinib
Incyte Corporation
Phase 3
617
Berlin, Bochum, Darmstadt, Dessau, Dresden, Düsseldorf, Erlangen, Frankfurt
2024-01-30
Recruiting
Total en Bloc Urethra Preservation at Robot-assisted Prostatectomy IDEAL Stage 2a
NCT07678489Prostate Cancer (Localized), Urinary Incontinence (C61)
Sami-Ramzi Leyh-Bannurah
Not applicable
60
Düsseldorf, Siegen
2024-01-30
Recruiting
Radiofrequency (RF) Ablation Prospective Outcomes Study for Central Nervous System - RAPID for CNS
NCT06553625Parkinson Disease, Dystonia, Essential Tremor, Movement Disorders
Boston Scientific Corporation
Observational
200
Cologne, Düsseldorf, Würzburg
2024-01-29
Active, closed
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
NCT06143878Plaque Psoriasis
DrugsIcotrokinra·Deucravacitinib
Janssen Research & Development, LLC
Phase 3
774
Berlin, Bramsche, Dresden, Düsseldorf, Hamburg, Kiel, Langenau, Leipzig
2024-01-17
Recruiting
Preventing Gastrointestinal Disturbance in Patients After Longitudinal Laparotomy.
NCT05923086Ileus Postoperative
DrugLidocaine
Orexa BV
Phase 2
126
Bonn, Düsseldorf, Wolfsburg
2024-01-11
Active, closed
RZ358 Treatment for Congenital Hyperinsulinism
NCT06208215Congenital Hyperinsulinism
Rezolute
Phase 3
56
Berlin, Düsseldorf
2024-01-11
By invitation
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
NCT06191315Wheezing, Asthma
DrugDupilumab
Sanofi
Phase 3
90
Düsseldorf, Frankfurt, Leipzig
2024-01-03
Recruiting
Identification of Risk Factors, Exposomics and Genetic Susceptibility of Melanoma in Children, Adolescents and Young Adults
NCT06680323Melanoma, Spitzoid Melanoma, Congenital Nevi
University Hospital Tuebingen
Observational
200
Düsseldorf
2024-01-01
Recruiting
Estimation of Outcome and Quality of Life in ECMO Patients
NCT06400797Extracorporeal Membrane Oxygenation
Heinrich-Heine University, Duesseldorf
Observational
1,000
Düsseldorf
2024-01-01
Active, closed
Systematic Assessment of Treatment Effectiveness for Long-Term Management of Stable Atrial Tachycardia in Inpatient and Outpatient Environments
NCT07239804Atrial Tachycardia, Stroke, Mortality, Atrial Flutter
Evangelical Hospital Düsseldorf
Observational
1,000
Düsseldorf, Hamburg, Karlsruhe, Münster
2024-01-01
Not yet open
Genomics in Heart Transplants
NCT06012162Heart Transplantation
Heinrich-Heine University, Duesseldorf
Observational
200
Düsseldorf
2024-01
Recruiting
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)
DrugSurovatamig
AstraZeneca
Phase 1/2
255
Berlin, Cologne, Düsseldorf, Essen, Frankfurt, Freiburg im Breisgau, Halle, Hamburg
2023-12-29
Active, closed
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
NCT06141486Multiple Sclerosis
DrugFrexalimab
Sanofi
Phase 3
943
Bielefeld, Bochum, Dresden, Düsseldorf, Erbach im Odenwald, Essen, Heidelberg, Jena
2023-12-27
Active, closed
A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine
NCT06087627Prurigo Nodularis
DrugDupilumab
Sanofi
Observational
110
Adernach, Berlin, Chemnitz, Düren, Düsseldorf, Hamburg, Leipzig, Mainz
2023-12-27
Active, closed
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT06141473Multiple Sclerosis
DrugsCholestyramine·Activated Charcoal·Teriflunomide·Frexalimab
Sanofi
Phase 3
1,655
Bielefeld, Bochum, Böblingen, Dresden, Düsseldorf, Erbach im Odenwald, Essen, Giessen
2023-12-13
Recruiting
LUPUS-BEST - Treat-to-target in Systemic Lupus Erythematosus
NCT05714930Systemic Lupus Erythematosus
Heinrich-Heine University, Duesseldorf
Not applicable
606
Freiburg im Breisgau, Heidelberg, Erlangen, Munich, Frankfurt am Main, Hanover, Düsseldorf, Essen
2023-12-12
Active, closed
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT06065748Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
DrugsGiredestrant·Ribociclib·Abemaciclib·Palbociclib
Hoffmann-La Roche
Phase 3
1,050
Bamberg, Cologne, Düsseldorf, Erlangen, Essen, Freiburg im Breisgau, Heidelberg, Homburg/Saar
2023-12-11
Rows per page Showing 101–200 of 420
Previous 1 2 3 4 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 September 2026. https://priyalifescience.com/clinical-trials-germany/city/d-sseldorf?page=2

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 420 of those studies with a site in Düsseldorf.

How many clinical trials are recruiting in Düsseldorf?

240 of the 420 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 20 have not yet opened recruitment, 153 are active but closed to new participants, and 7 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.